February 13, 2017
Ipsen acquires Sanofi’s five products for €83M
Ipsen has entered into a definitive agreement to acquire Sanofi’s five consumer healthcare products in certain European territories.
Pharmaceuticals, Biotechnology and Life Sciences
Author: Dino Mustafić
February 13, 2017
Verona Pharma 10million newly consolidate ordinary shares
Verona Pharma said on Monday that, after the 50 for 1 share consolidation approved by shareholders on 8 February 2017, it now has 51,361,064 ordinary shares of £0.05 each in issue, each carrying one voting right.
February 13, 2017
Oxford BioDynamics welcomes Dr Claudio Carini to its Scientific Advisory Panel
Oxford BioDynamics, a biotechnology company focused on the discovery and development of novel epigenetic biomarkers for use within the pharmaceutical and biotechnology industry, has appointed Dr Claudio Carini as an Advisor, effective immediately.
February 13, 2017
STADA on target for two bidders, one being private equitiy firm Cinven
German drugmaker Stada has confirmed certain rumours about receiving takeover offers from a private equity firm, Cinven Partners and one other unnamed bidder.
February 13, 2017
Evgen Pharma inks services deal with APTrans
Evgen Pharma has signed a services agreement with APTrans for developing its anti-stress drug SFX-01, currently in phase II clinical testing. APTrans is a Cheshire-based consortium of drug development companies.
February 13, 2017
Premaitha signs four-year MPA with European diagnostics services group to install IONA test
Premaitha has signed four-year Master Procurement Agreement (the “MPA”) with a European diagnostics services group to install the IONA test in at least two of the Groups’s laboratories.
February 10, 2017
Redx positive about its prospects, raises £7million
“The new funds we are raising will support the ongoing progress of these important assets as well as the rest of our pipeline and we remain very positive about Redx’s prospects.”
February 10, 2017
U.S. scientists get $87 million Grand Challenge awards to quicken battle against cancer
Cancer Research UK (CR UK), the world’s largest not-for-profit cancer research organization, has today announced that six leading U.S. scientists are among the winners of a global competition to help overcome the biggest challenges facing cancer research.
February 10, 2017
Immunomedics, Seattle Genetics in $2B cancer drug deal. ‘Seattle’ buys 2.8% stake
Immunomedics Inc has concluded a $2 billion worth deal with Seattle based developer of antibody-drug conjugates (ACDs) for treating late stage cancer based on which Seattle Genetics will develop, fund, manufacture and commercialize IMMU-132, Immunomedics’ proprietary solid tumor therapy candidate.
February 10, 2017
Neurocrine, BIAL in exclusive USA and Canada licensing Opicapone deal
Neurocrine Biosciences has made a deal with BIAL to develop and sell Ongentys opicapone inhibitor for Parkinson’s patients, in North America.